Free Mark Cuban Foundation AI Bootcamp Coming to Philadelphia This Fall

The Mark Cuban Foundation, in partnership with CSL, will host a no-cost Artificial Intelligence Bootcamp for high school students in Philadelphia this fall. The program is open to students in grades 9–12 and will take place over three consecutive Saturdays November 1, 8, and 15, 2025 from 11 a.m. to 4 p.m. Meals, transportation assistance, and technology will be provided at no cost to participating students.

The AI Bootcamp gives underserved students hands-on experience with cutting-edge AI tools, including generative AI, and explores real-world applications in fields such as healthcare, arts, business, computer science, sports science, and career readiness. Students will also complete a capstone project under the guidance of industry mentors.

Mark Hill, Chief Digital & Information Officer, CSL, said, "To be ready for the future, students must be ready for AI. This technology is already changing how we discover new medicines, create art, and solve community challenges. CSL is proud to partner with the Mark Cuban Foundation to ensure Philadelphia students from all backgrounds gain real-world AI experience, mentorship, and the inspiration to imagine what's possible for themselves and their communities."

Since 2019, the Mark Cuban Foundation AI Bootcamp has served thousands of students nationwide, working to bridge the digital divide and provide equitable access to AI education. The 2025 program introduces a dedicated Teacher Fellow in every location, supporting local educators through a year-long paid fellowship

Mark Cuban, founder of the Mark Cuban Foundation, emphasized, "Our goal is to ensure that every interested student, regardless of background or resources, can explore AI and its limitless possibilities."

Applications are encouraged from girls, students of color, first-generation college-goers, and students from low-income backgrounds. The deadline to apply is September 30, 2025.

To apply or learn more, visit markcubanai.org.

About Mark Cuban Foundation's AI Bootcamp Initiative

The Mark Cuban Foundation is a 501(c)(3) private nonprofit led by entrepreneur and investor Mark Cuban. The AI Bootcamps Program inspires young people with emerging technology so they can create more equitable futures for themselves and their communities. Over three Saturdays, students learn what AI is and isn't, explore ethical implications, and understand how AI impacts their lives. Learn more at markcubanai.org.

About CSL

CSL (ASX:CSL,OTC:CMXHF; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/ Vita and follow us on X.com/CSL .

For more information about CSL Limited, visit www.CSL.com .

Media Contact:
Bishop.wash@markcubanai.org


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CSL:AU
The Conversation (0)
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×